Figure 5.

Fluorescence optical imaging of UM-SCC-22B tumors and cell clusters using IRDye 800-cetuximab. (A) Longitudinal fluorescence imaging of subcutaneous UM-SCC-22B xenografted tumors. Each animal received around 1 nmol of IRDye800-centuximab via tail vein. The tumors (white arrows) were clearly visualized from 4 h to 96 h after injection. (B) Quantitative analysis of fluorescence intensity within tumor and background area. The leg muscle was chosen as the background. (C) Quantitative analysis of tumor to background ratio (TBR). (D) Evaluation of sensitivity of IRDye800-cetuximab in tumor cell detection. Different amount UM-SCC-22B cells were inoculated subcutaneously in nude mice (n=4). Twenty-four hours after tumor cell inoculation, IRDye800-cetuximab (1 nmol of dye in 150 μL) was injected via tail vein. Another 24 h later, optical imaging was performed using a NIR filter set (excitation 704 nm, emission 745 nm longpass). The cell cluster containing 1K cells were clearly visualized. (E) Quantitative analysis of ratio of signal intensity from tumor cell clusters to background area.